Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

Fig. 4

CSF p-tau in the WUSTL amyloid-positive cohort. CSF concentration of pT181 (E_pT181) was measured by ELISA (in pg/mL) (a), MS_pT181 (b), and MS_pT217 (c) were measured by quantitative MS (in fmol/mL) in amyloid (−) and (+) populations. The ROC curves of the detection of the amyloid (+) patients for E_pT181, MS_pT181, and MS_pT217 were plotted (d) (see SupTable 3 for statistical differences between curves). The MS_pT217 values (e) and percentage of T217 phosphorylation (% MS_pT217, f) were plotted against their corresponding PiB-PET values in the WUSTL cohort composed of amyloid (−) and (+) patients. Linear regression and correlation coefficients are indicated

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193